Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by antirheumatic drugs

Journal of Laboratory and Clinical Medicine

Volumn 128, Issue 6, 1996, Pages 552-560

  Bratt, J ^a   Palmblad, J ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030377418     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90127-4     Document Type: Article

References (41)

1. Weiss SJ, Young J, LoBuglio AF, Slivka A, Nimeh NF. Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 1981;68:714-21.
2. Ward PA, Varani J. Mechanisms of neutrophil-mediated killing of endothelial cells. J Leukocyte Biol 1990;48:97-102.
3. Fauci AS, Leavitt RY. Vasculitis, arthritis, and allied conditions. 12th ed. Mccarty DJ, editor. Philadelphia: Lea and Febiger, 1993:1301-23.
4. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
5. Harlan JM, Schwartz BR, Reidy MA, Schwartz SM, Ochs HD, Harker L. Activated neutrophils disrupt endothelial monolayer integrity by an oxygen radical-independent mechanism. Lab Invest 1985;52:141-50.
6. Bratt J, Lerner R, Ringertz B, Palmblad J. Lipoxin A4 induces neutrophil dependent cytotoxicity for human endothelial cells. Scand J Immunol 1994;39:351-4.
7. Becker EL, Sigman M, Oliver JM. Superoxide production induced in rabbit polymorphonuclear leukocytes by synthetic chemotactic peptides and A23187. Am J Pathol 1979;95:81-97.
8. Hafström I, Udén AM, Palmblad J. Modulation of neutrophil functions by auranofin. Scand J Rheumatol 1983;12:97-105.
9. Finkelstein AE, Roisman FR, Ladizesky MG, Walz DT. Auranofin and lysosomal enzymes. J Rheumatol 1982; 8(suppl):46-53.
10. Parente JE, Wong K, Davis P, Burka JF, Percy JS. Effects of gold compounds on leukotriene B4, leukotriene C4, and prostaglandin E2 production by polymorhonuclear leukocytes. J Rheumatol 1986;13:47-51.
11. Davis P, Johnston C, Miller CL, Wong K. Effects of gold compounds on the function of phagocytic cells. Inhibition of superoxide radical generation by tripeptide-activated polymorphonuclear leukocytes. Arthritis Rheum 1983;26:82-6.
12. Corey EJ, Mehrotra MM, Khan AU. Antiarthritic gold compounds effectively quench electronically excited singlet oxygen. Science 1987;236:68-9.
13. Finkelstein AE, Roisman FR, Walz DT. Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes. Inflammation 1977;2:143-50.
14. Kawakami A, Eguchi K, Migita K, Nakao H, Otsubo T, Ueki Y, et al. Inhibitory effects of gold sodium thiomalate on the proliferation and interferon-γ-induced HLA-DR expression in human endothelial cells. J Rheumatol 1990;17:430-5.
15. Corkill MM, Kirkham BW, Haskard DO, Barbatis C, Gibson T, Panayi GS. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 1991;18:1453-60.
16. Neal TM, Winterbourn CG, Vissers MCM. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Biochem Pharmacol 1987;36:2765-8.
17. Kanerud L, Hafström I, Ringertz B. Effect of sulfasalazine and sulfapyridine on neutrophil superoxide production: role of cytosolic free calcium. Ann Rheum Dis 1990;49:296-300.
18. 245. Aliment Pharmacol Ther 1991;5:609-19.
19. Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor α: a novel mechanism of action of sulfasalazine. Gut 1993;34:252-6.
20. Sharon P, Drab DB, Linder JS, Weidman SW, Sabesin SM, Rubin DB. The effect of sulfasalazine on bovine endothelial cell proliferation and cell cycle phase distribution. Comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine. J Lab Clin Med 1992;119:99-107.
21. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32:1065-73.
22. O'Callaghan JW, Forrest MJ, Brooks PM. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int 1988;8:41-5.
23. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci 1991;88:2441-5.
24. Asako H, Kubes P, Baethge BA, Wolf RE, Granger DN. Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 1992;16:45-56.
25. Palmblad J, Lerner R, Larsson SH. Signal transduction mechanisms for leukotriene B4 induced hyperadhesiveness of endothelial cells for neutrophils. J Immunol 1994;152: 262-9.
26. Ringertz B, Palmblad J, Lindgren JÅ. Stimulus-specific neutrophil aggregation: evaluation of possible mechanisms for the stimulus-response apparatus. J Lab Clin Med 1985;106: 132-40.
27. Bratt J, Lerner R, Ringertz B, Palmblad J. Mechanisms for lipoxin A4 induced neutrophil dependent cytotoxicity for human endothelial cells. J Lab Clin Med 1995;126:36-43.
28. Cronstein BN, Levin RI, Belanoff J, Weissman G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78:760-70.
29. Hafström I, Seligmann BE, Friedman MM, Gallin J. Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli. J Immunol 1984;132:2007-13.
30. Rudkowski R, Ziegler JB, Graham GG, Joulianos G. Gold complexes and activation of human polymorphonuclear leukocytes. Dissociation of changes in membrane potential and oxidative burst. Biochem Pharmacol 1992;44:1091-8.
31. Schröder H, Campbell DES. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972;13:539-51.
32. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulfasalazine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut 1980;21:632-5.
33. Stenson WF, Metha J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (fMLP) to its receptor on human neutrophils. Biochem Pharmacol 1984;33:407-12.
34. Ahnfelt-Rönne I, Haagen Nielsen O, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990;98:1162-9.
35. Palmblad J, Gyllenhammar H, Ringertz B. Effects of lipoxins A and B on functional responses of human granulocytes. Adv Exp Med Biol 1987;229:137-45.
36. Suarez CR, Pickett WC, Bell DH, Mcclintock DK, Oronsky AL, Kerwar SS. Effect of low dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C5a. J Rheumatol 1987;14:9-11.
37. Allgayer H, Stenson W. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs exogenous arachidonic acid. Immunopharmacol 1988;15:39-46.
38. Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990;33:1149-55.
39. Moncada SR, Palmer MJ, Higgs EA. Nitric oxide: physiology, patophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-42.
40. Salvemini D, De Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci USA 1989;86:6328-32.
41. Bratt J, Gyllenhammar H. The role of nitric oxide in lipoxin A4-induced polymorphonuclear neutrophil-dependent cytotoxicity to human vascular endothelium in vitro. Arthritis Rheum 1995;38:768-76.